Counsyl’s Women's Health division is focused on providing best-in-class DNA testing and genetic counseling services, coupled with software solutions that streamline the process and improve the experience for both clinicians and patients alike.
As a Clinical Account Executive, you’ll be in the field representing Counsyl and working with women's health physicians to integrate our technologically advanced products into their day-to-day workflow. You’ll be the mini-CEO of your territory, responsible for your territory’s P&L and expanding your base book of business.
You’re polished, analytical, and know how to energize potential clients. You've worked in a competitive market and have the ability to differentiate based on value and first-in-class products. You want to be a part of a mission-driven company that is focused on providing affordable products to patients.
Counsyl is a health technology company that offers DNA screening for diseases that can impact men, women and their children. The Counsyl philosophy is simple: screen for diseases where advanced knowledge makes a difference in health outcomes, whether it’s changing a behavior, pursuing preventative measures, or simply preparing for what lies ahead.
The Counsyl team includes an accomplished group of problem-solvers — top engineers, scientists, and designers — who are taking the lead on building the modern clinical laboratory. Scientific rigor, custom robotics, and software are at the heart of every Counsyl product, resulting in better, faster and more affordable screens that are broadly accessible. Beyond the laboratory, Counsyl offers doctors and patients a technology platform for results delivery in real time, with on-demand access to board-certified genetic counselors.
Counsyl has screened more than 750,000 patients and served more than 10,000 health care professionals in its CLIA-certified, CAP-accredited and NYS CLEP-permitted clinical laboratory. The company has raised a total of $102 million and is privately backed by Pilot Growth Equity, Goldman Sachs Asset Management, Founders Fund, Felicis Ventures, David Drummond, and other high profile investors.